Preferred Label : Anti-VSIG4 Monoclonal Antibody EU103;
NCIt definition : A humanized immunoglobulin G1 kappa (IgG1kappa) monoclonal antibody directed against
V-set and immunoglobulin domain-containing 4 (VSIG4), with potential immunomodulating
and antineoplastic activities. Upon administration, anti-VSIG4 monoclonal antibody
EU103 targets, binds to and inhibits the activity of VSIG4 expressed on immunosuppressive
M2 macrophages. This induces repolarization of these tumor-associated macrophages
(TAMs) and leads to macrophage conversion of M2 into M1 macrophages. This improves
the tumor microenvironment (TME), blocks VSIG4-mediated T-cell suppression, and leads
to a cytotoxic T-cell-mediated anti-tumor immune response. VSIG4, one of the B7 family-related
proteins, is overexpressed in various tumor cell types. Its overexpression negatively
regulates T-cell proliferation and is correlated with poor prognosis.;
Molecule name : EU 103; EU-103;
NCI Metathesaurus CUI : CL1907540;
Origin ID : C200550;
UMLS CUI : C5854559;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
